BRD4 and chronic myelogenous leukemia, BCR-ABL1 positive: It is worth noting in this regard that most BRD4/MYC blockers and especially the BRD4 degraders also exhibit strong direct anti-neoplastic effects on AML LSC [120,121], and may overcome multiple forms of LSC resistance in AML and CML (P.V., unpublished observation).